Related Experiment Video
Updated: May 20, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Adalimumab in psoriatic arthritis
Carlo Salvarani1, Nicolò Pipitone, Mariagrazia Catanoso
1Rheumatology Unit, Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy. salvarani.carlo@asmn.re.it
The Journal of Rheumatology. Supplement
|July 4, 2012
Summary
Adalimumab (ADA) effectively treats psoriatic arthritis (PsA) symptoms and inhibits structural damage. Long-term ADA treatment shows sustained efficacy and a favorable safety profile for PsA patients.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Psoriatic arthritis (PsA) presents diverse musculoskeletal manifestations.
- Adalimumab (ADA) has demonstrated short-term efficacy in PsA and psoriasis.
Purpose of the Study:
- To evaluate the efficacy and safety of adalimumab (ADA) in psoriatic arthritis (PsA).
- To assess the long-term effectiveness and radiographic impact of ADA in PsA patients.
Main Methods:
- Review of open prospective studies and randomized controlled trials (RCTs) on ADA in PsA.
- Assessment of musculoskeletal manifestations, disability, quality of life, and radiographic changes.
- Magnetic resonance imaging (MRI) used to evaluate bone marrow edema and erosions.
Main Results:
- ADA effectively treated peripheral arthritis, spinal disease, enthesitis, and dactylitis in PsA.
- Significant inhibition of radiographic structural changes, reduced disability, and improved quality of life observed.
- Short-term efficacy was sustained in long-term treatment; safety profile comparable to rheumatoid arthritis studies.
- Combination therapy with cyclosporine may offer enhanced efficacy in specific PsA patient subgroups.
Conclusions:
- Adalimumab (ADA) demonstrates sustained clinical and radiographic efficacy in psoriatic arthritis (PsA).
- ADA possesses a favorable risk-benefit profile for managing PsA.
- Further RCTs are needed to confirm the benefits of ADA combined with cyclosporine.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...